Astrotech Corporation — Form 10-Q Summary
Reporting period: The filing covers the three months ended September 30, 2022, the first quarter of fiscal 2023, and is unaudited. This differs from the request metadata’s “2021 Q1.” Financial amounts below are in U.S. dollars; figures are in millions unless stated otherwise.
Business context
Astrotech commercializes mass spectrometry technology through wholly owned subsidiaries focused on security detection (1st Detect), agriculture and extraction processing (AgLAB), and breath-based disease screening (BreathTech). Its TRACER 1000 has European certification and was deployed at about 20 locations in 11 countries. U.S. TSA cargo detection testing remained ongoing. AgLAB began its first AgLAB-1000-D2 production run during the quarter; sales efforts were underway. BreathTest-1000 development and disease-screening work with Cleveland Clinic continued.
Financial performance and liquidity
| Metric | Quarter ended Sep. 30, 2022 | Prior-year quarter |
|---|---|---|
| Revenue | $0.038 | $0.187 |
| Gross profit / margin | $0.006 / 16% | $0.012 / 6% |
| Operating expenses | $2.771 | $2.065 |
| Operating loss | $2.765 | $2.053 |
| Net loss | $2.530 | $2.029 |
| Net loss per share | $0.05 | $0.04 |
| Cash used in operating activities | $2.441 | $2.186 |
Revenue fell about 80%, largely because the company shifted sales focus away from the explosives trace detector market and toward AgLAB. The company attributed the higher gross margin to a greater share of recurring services and materials rather than system sales. SG&A rose $0.216 million, including legal, director-fee, and customer-support costs; R&D rose $0.490 million, primarily for AgLAB trials and development and BreathTech sample collection.
At September 30, cash and cash equivalents were $18.273 million and short-term investments were $30.675 million. Working capital was approximately $49.4 million. Cash declined $8.180 million during the quarter, including $4.855 million of purchases of investments, $2.441 million of operating cash use, and $0.538 million of financing cash use. Total liabilities were $2.129 million. The $0.500 million related-party note was repaid at maturity in September; remaining lease liabilities were $0.480 million. No material off-balance-sheet arrangements were reported.
Material changes, outlook and risks
- Net loss increased by $0.501 million year over year as operating expenses grew faster than the reduction in revenue. Other income and expense, net, was positive $0.235 million versus $0.024 million.
- Available-for-sale investments had $1.567 million of cumulative unrealized losses at quarter-end; the quarter’s other comprehensive loss included $0.368 million of additional unrealized losses.
- Management gave no quantified revenue or earnings guidance. It said it expected to fund operations from available resources and did not expect supply-chain issues to materially harm liquidity, while cautioning that prolonged shortages could hurt business and results.
- COVID-related TSA testing delays, semiconductor and electronics shortages, higher product and shipping costs, uncertain airline-sector recovery, and customer adoption risks could affect results. Revenue came from three customers in the quarter.
- Nasdaq had extended the deadline to regain the $1.00 minimum bid-price requirement to December 19, 2022. Failure to regain compliance could lead to delisting, subject to appeal.
- A Delaware stockholder class and derivative action had a settlement in principle, with approval anticipated for December 12, 2022. The filing does not state a clear expected settlement cost.
- After quarter-end, the board authorized a share repurchase program of up to $1.0 million for November 17, 2022 through November 17, 2023, subject to management discretion. The company also extended its Austin office lease through March 2025, with about $87,000 of base rent for the ten-month extension.
Important facts for investors to verify
- Whether AgLAB production converts into material sales and whether its products achieve the expected customer demand and margins.
- Progress and timing of TSA cargo detection testing and the status of Nasdaq minimum-bid-price compliance.
- Cash and short-term investment balances, operating cash burn, and how any share repurchases affect available capital.
- Supply-chain costs, customer concentration, and the pace of BreathTech development and clinical sample collection.
- Outcome and financial terms of the anticipated litigation settlement; the filing does not provide a clear expected loss amount.